English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Molecular mechanism for plant steroid receptor activation by somatic embryogenesis co-receptor kinases

MPS-Authors
/persons/resource/persons273396

Santiago,  J
Hothorn Group, Friedrich Miescher Laboratory, Max Planck Society;

/persons/resource/persons273398

Henzler,  C
Hothorn Group, Friedrich Miescher Laboratory, Max Planck Society;

/persons/resource/persons271947

Hothorn,  M
Hothorn Group, Friedrich Miescher Laboratory, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Santiago, J., Henzler, C., & Hothorn, M. (2013). Molecular mechanism for plant steroid receptor activation by somatic embryogenesis co-receptor kinases. Science, 341(6148), 889-892. doi:10.1126/science.1242468.


Cite as: https://hdl.handle.net/21.11116/0000-000A-6760-6
Abstract
Brassinosteroids, which control plant growth and development, are sensed by the leucine-rich repeat (LRR) domain of the membrane receptor kinase BRASSINOSTEROID INSENSITIVE 1 (BRI1), but it is unknown how steroid binding at the cell surface activates the cytoplasmic kinase domain of the receptor. A family of somatic embryogenesis receptor kinases (SERKs) has been genetically implicated in mediating early brassinosteroid signaling events. We found a direct and steroid-dependent interaction between the BRI1 and SERK1 LRR domains by analysis of their complex crystal structure at 3.3 angstrom resolution. We show that the SERK1 LRR domain is involved in steroid sensing and, through receptor-co-receptor heteromerization, in the activation of the BRI1 signaling pathway. Our work reveals how known missense mutations in BRI1 and in SERKs modulate brassinosteroid signaling and the targeting mechanism of BRI1 receptor antagonists.